ASCO 2022 Conference Coverage

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

ASCO 2022 Conference Coverage

Breast
Lung
GI
GU
Skin
GYN
Head & Neck
Leukemia
Lymphoma
Myeloma
MDS and MPN
Sarcoma

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

ASCO 2022 on Overall Survival by IDH2 Mutant Allele (R140 or R172) in Late-Stage Mutant-IDH2 R/R AML Treated With Enasidenib or Conventional Care Regimens in the Phase 3 IDHENTIFY Trial

By ASCO 2022 Conference Coverage FEATURING Stéphane De Botton

0 views

July 9, 2022

Comments 0

SERDS: Relevance and Role in Current & Future Treatments for HR+…

Feat. K. Jhaveri

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse

Leukemia

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Efficacy & Safety Results From the P…

Feat. J. Cortés